![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
About the Morgan Adams Foundation
|
The Morgan Adams Memorial Neuro-Oncology Research Fund The Morgan Adams Memorial Neuro-Oncology research fund at The Children’s Hospital in Denver was started in November of 1998, after Morgan, age 6, lost her battle with a glioblastoma multiforme brain tumor. In 2001, artma, and in 2003, The Morgan Adams Concours d’Elegance were conceived as new ways to increase the fund resources, thereby giving greater support to research efforts being conducted in neuro-oncology and other areas of childhood cancer. These events have received an incredible show of support from the community – and together have contributed close to $375,000 to the fund. Below we have accounted for how that money has been spent. We are proud of what has been accomplished, but there is much work to be done. Thank you for helping us support for these and other crucial projects!
Gene chip analysis and prediction of prognosis in ependymoma.
$35,000 A quarter of a salary for our data bank and IRB submission needs. $20,000 Study of how to stream line and make more effective applications for financial assistance for the indigent families of children with brain tumors (K. Tilley). $2,000.00 Scientific trials in the late-effect-clinics to determine benefits of interventions to improve quality of life (Bassel). $15,000.00
Interaction between spinal block radiation and thiotepa on risk of liver veno-occlusive disease. Clinical study with laboratory correlates. $15,000.00 - 20,000.00 Phase I/II study of oxaliplatin and thiotepa in GBMs ( Denver as site center for multi-centered trial – L.Gore). $10,000.00 - 15,000.00 Neurosurgical studies – TBD. $20,000.00
Medulloblastoma, molecular prognostic testing (collaboration with MD Anderson). $3000 Factors causing bleeding in newly diagnosed patients with brain tumors. (A. Smith). $32,000 Survivin as a prognostic marker in medulloblastoma and ATRT. (A.Smith). Initial $2000, subsequent funding obtained elsewhere Apoptosis (programmed) cell death in GBM and Caspase Expression. (J. Fleitz). $15,000 Ganglioside expression and immunosuppression in GBM. (J. Fleitz and N. Foreman). $45,000 Ganglioside modification and development of improved tumor vaccine in GBM. (N. Foreman). Initial $22,000, then subsequent funding applied for by ABTA. PKC zeta expression and potential as a target for initial therapy in GBM. (N.Foreman). $10,000 Development of novel therapies in pediatric brain tumor (e.g.Temodar/VP16 in recurrent GBM). $15,000 Support for development of consortium for rapid trials of pediatric brain tumors. (Eight center consortium including Toronto Sick Children’s, MD Anderson, LA Children’s). $20,000 Commitment for play therapy trial for pediatric brain tumors. $5,000 Presentation of results at national and international meetings. Approximately $3,000 Choroid Plexus Carcinoma and Rhabdoid Tumors: Phenotypic and Genotypic Overlap. (Ashmead & Foreman). $3,000 Cytogenetics in Low-grade Astrocytomas. (Orr and Foreman). $2,500 Generalized phase I studies in pediatric malignancies – program development (L. Gore). $50,000 |
|
|---|---|---|
The
Morgan Adams Foundation | 5303 E. Evans Avenue, Suite 202, Denver, CO 80222 |
(303) 758-2130 Copyright © 2005-07. All rights reserved. |
||